Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma by Claudius Irlé, Jonathan Weintraub

“…The patient eventually underwent a successful autologous stem cell transplant. This case illustrates the successful use of romidepsin for the long-term treatment of a patient with AITL in a clinical setting. …”
Get full text

Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD by Philip T. Sobash, Achuta K. Guddati, Vamsi Kota

“…We present a case of a 32-year-old male on ruxolitinib with GVHD status postmatched unrelated donor stem cell transplant (MUD SCT) for acute myeloid leukemia (AML) with FLT3 mutation currently on ruxolitinib for 5 years who is not able to tolerate reduction in dosage due to flare-ups. …”
Get full text

Humoral immune response after anti-SARS-CoV-2 vaccine “booster” dose in patients with monoclonal gammopathy of undetermined significance (MGUS) by NICOLA SGHERZA, Paola Curci, Rita Rizzi, Angela Maria Vittoria Larocca, Luigi Vimercati, Silvio Tafuri, Maria Chironna, Pellegrino Musto

Get full text

Prolonged Pediatric Extracorporeal Membrane Oxygenation Support with Cardiopulmonary Failure in Juvenile Myelomonocytic Leukemia by Maris Bartkevics, Bert Hennig, Tayfun Gungor, Roland Ammann, Alexander Kadner

Get full text

Cavernous Nerve Injury Resulted Erectile Dysfunction and Regeneration by Nan Jiang, Cheng Wu, Xunrong Zhou, Guanghua Zhai, Jian Wu

“…In addition, such as neuromodulatory proteins, proimmune ligands, gene therapy, stem cell therapy, and the current cutting-edge low-energy shock wave therapy have shown advantages in basic research and limited clinical studies. …”
Get full text

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas by Marco Gunnellini, Lorenzo Falchi

“…Alternative chemoimmunotherapy regimens are often used as salvage strategy and stem cell transplant remains an option for selected patients. …”
Get full text

Pharmacological or genetic inhibition of LTCC promotes cardiomyocyte proliferation through inhibition of calcineurin activity by Lynn A. C. Devilée, Abou bakr M. Salama, Jessica M. Miller, Janice D. Reid, Qinghui Ou, Nourhan M. Baraka, Kamal Abou Farraj, Madiha Jamal, Yibing Nong, Todd K. Rosengart, Douglas Andres, Jonathan Satin, Tamer M. A. Mohamed, James E. Hudson, Riham R. E. Abouleisa

“…A drug screen targeting proteins involved in CM calcium cycling in human embryonic stem cell-derived cardiac organoids (hCOs) revealed that only the inhibition of L-Type Calcium Channel (LTCC) induced the CM cell cycle. …”
Get full text

Inflammatory Serum Biomarkers in Colorectal Cancer in Kazakhstan Population by L. Akhmaltdinova, V. Sirota, V. Zhumaliyeva, D. Babenko, I. Kadyrova, Z. Tauesheva, D. Taizhanova, A. Ibraeva, M. Maratkyzy, A. Turmukhambetova

“…The following biomarkers were included in the study panel: stem cell factor (SCF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF2), interleukin 6 (IL6), interleukin 8 (IL8), macrophage migration inhibitory factor (MIF), soluble Fas (SFAS), soluble Fas ligand (sFASL), transforming growth factor β (TGF), tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), and programmed death ligand 1 (PD-L1). …”
Get full text

Nanobody-thioesterase chimeras to specifically target protein palmitoylation by Chien-Wen Kuo, Caglar Gök, Hannah Fulton, Eleanor Dickson-Murray, Samuel Adu, Emily K. Gallen, Sheon Mary, Alan D. Robertson, Fiona Jordan, Emma Dunning, William Mullen, Godfrey L. Smith, William Fuller

“…Using a thioesterase fused to a nanobody directed against the Ca(v)1.2 beta subunit we reduce palmitoylation of the Ca(v)1.2 alpha subunit, modifying the channel’s voltage dependence and arrhythmia susceptibility in stem cell derived cardiac myocytes. We conclude that nanobody enzyme chimeras represent an approach to specifically manipulate PTMs, with applications in both the laboratory and the clinic.…”
Get full text

Sarcopenia and cachexia: molecular mechanisms and therapeutic interventions by Tiantian Wang, Dong Zhou, Zhen Hong

“…This review discusses the muscle microenvironment's changes contributing to these conditions, recent therapeutic approaches like lifestyle modifications, small molecules, and nutritional interventions, and emerging strategies such as gene editing, stem cell therapy, and gut microbiome modulation. We also address the challenges and opportunities of multimodal interventions, aiming to provide insights into the pathogenesis and molecular mechanisms of sarcopenia and cachexia, ultimately aiding in innovative strategy development and improved treatments.…”
Get full text

Molecular Monitoring in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with the Variant e13a3 BCR-ABL1 Fusion by Mireille Crampe, Laura Kearney, David O’Brien, C. Larry Bacon, Derville O’Shea, Stephen E. Langabeer

“…Molecular monitoring reflected the disease response from diagnosis through allogeneic stem cell transplantation which resulted in undetectable e13a3 BCR-ABL1 transcripts. …”
Get full text

Progress Research in the Immune-Actinopathies and Pathogenic Genes by MA Shiyun, ZHOU Lina, AN Yunfei, ZHAO Xiaodong

“…Future research will focus on the identification of new immunoactinopathy-caused genes and its mechanism, discovery of new precision therapeutic target, development of drugs, improvement of hematopoietic stem cell transplantation strategies, and discovery of new gene therapy. …”
Get full text

HSCT-GAVE as a Manifestation of Chronic Graft versus Host Disease: A Case Report and Review of the Existing Literature by Michael J. Grant, Mitchell E. Horwitz

“…Over 30 cases of hematopoietic stem cell transplant-related GAVE (HSCT-GAVE) have been reported in the literature to date and there are likely many more that go undiagnosed or are attributed to another cause of upper gastrointestinal bleeding. …”
Get full text

Proteomic profiling of iPSC and tissue-derived MSC secretomes reveal a global signature of inflammatory licensing by Margeaux Hodgson-Garms, Matthew J. Moore, Mikaël M. Martino, Kilian Kelly, Jessica E. Frith

“…This study analysed the secretomes of bone-marrow (BM.MSCs), umbilical-cord (UC.MSCs), adipose-tissue (AT.MSCs) and clinical/commercial-grade induced pluripotent stem cell-derived MSCs (iMSCs), under resting and inflammatory licenced conditions. iMSCs recapitulated the inflammatory licensing process, validating their comparability to tissue-derived MSCs. …”
Get full text

Increased local DNA methylation disorder in AMLs with DNMT3A-destabilizing variants and its clinical implication by Dohoon Lee, Bonil Koo, Seokhyeon Kim, Jamin Byun, Junshik Hong, Dong-Yeop Shin, Choong-Hyun Sun, Jaesung Kim, Ji-Joon Song, Siddhartha Jaiswal, Sung-Soo Yoon, Sun Kim, Youngil Koh

“…This epigenetic heterogeneity was associated with the transcriptional variability of developmental and membrane-associated factors shaping stem cell niche, and also was a predictor of the response of AML cells to hypomethylating agents, implying that the survival of AML cells depends on stochastic DNA methylations at bivalent domains. …”
Get full text

Nanodrug‐Engineered Exosomes Achieve a Jointly Dual‐Pathway Inhibition on Cuproptosis by Hanxiao Sun, Yang Zou, Zhengtai Chen, Yan He, Kai Ye, Huan Liu, Lihong Qiu, Yufan Zhang, Yuexue Mai, Xinghong Chen, Zhengwei Mao, Wei Wang, Chenggang Yi

“…A Cu‐chelator (Clioquinol, CQ) polydopamine (PDA)‐modified stem cell exosome loaded with siRNA‐FDX1, named EXOsiFDX1‐PDA@CQ, is designed to efficiently inhibit the two cuproptosis pathways. …”
Get full text

Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients by Edward Kim, Alina Adeel, Adel Bozorgzadeh, Shinya Amano, Curtis T. Barry, Jennifer S. Daly, Deepika Devuni, Zendee Elaba, Laura Houk, Paulo N. Martins, Babak Movahedi, Muthalagu Ramanathan, Nicole M. Theodoropoulos

“…We report on two patients who developed aGvHD after liver transplantation who were treated with ruxolitinib, a novel Janus kinase 1/2 (JAK) inhibitor that has been shown to improve outcomes in steroid refractory cases of aGvHD after allogenic hematopoietic stem cell transplantation. We reviewed the literature to discuss various therapeutic options currently available for aGvHD after liver transplantation.…”
Get full text

Advancements in Antioxidant-Based Therapeutics for Spinal Cord Injury: A Critical Review of Strategies and Combination Approaches by Yang-Jin Shen, Yin-Cheng Huang, Yi-Chuan Cheng

“…This review provides a comprehensive and critical evaluation of recent advancements in antioxidant-based therapeutic strategies for SCI, including natural compounds, RNA-based therapies, stem cell interventions, and biomaterial applications. …”
Get full text

Persistent Mixed Donor Chimerism following Double Umbilical Cord Transplantation in a Patient with T-Cell Prolymphocytic Leukemia by Ronak H. Mistry, Elizabeth O. Hexner, James K. Mangan

“…Current standard of care for T-PLL is with alemtuzumab, followed by allogeneic or autologous stem cell transplant. Little is found in the literature about alternative donor transplantation in T-PLL. …”
Get full text

A Case Report of Clinical Characteristics of Deficiency of Adenosine Deaminase 2 with Pancytopenia by ZHANG Caihui, LIU Liying, ZHANG Zhenjie, WANG Wei, MA Mingsheng, SONG Hongmei

“…Treatment protocol should base on the disease phenotype and severity, and include glucocorticoids, immunosuppressants, biological agents, and hematopoietic stem cell transplantation.…”
Get full text